A Study of the Effects of Inflammation on Fat Tissue and Insulin in People with Different Body Shapes

Overview

Información sobre este estudio

The purpose of this study is to see why the ability of fat cells to respond to insulin is different depending on body shape and how fat tissue inflammation is involved.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria

  • Adult men and women over 18 – 55 years of age.
  • Obese participants with BMI of 27-37 kg/m2, type 2 DM participants with BMI 20-40 kg/m2 and non-obese participants with BMI <27kg/m2 who meet the predefined criteria for UBO, LBO, T2DM and non-obese.
  • Women should be premenopausal and men should be age matched to the premenopausal women of the same group.
  • Participants should be healthy enough to undergo the testing procedures and participate in a weight loss program.
  • For non-obese Alkaline Phosphatase, CBC, Electrolyte Panel, G.O. Transaminase (serum), Glucose and Lipid Profiles will all need values in the normal range. For obese and overweight participants only the CBC and electrolyte panel must be in the normal range; transaminase, glucose and lipid values are anticipated to be abnormal to a modest degree in obesity.
  • For Type II Diabetic volunteers they will need a HbA1C between 7.0% and 9.5%. As with obese participants (above), transaminase, glucose and lipid values are anticipated to be abnormal to a modest degree in many patients.
  • Participants should be able to give appropriate informed consent to participate in the study.
  • Participants should be weight stable for 2 months before the start of the study.

Exclusion Criteria

 

  • History of ischemic heart disease, atherosclerotic vascular disease or known systemic inflammatory (infectious, autoimmune) illness.
  • Blood pressure greater than 160/95 despite antihypertensive medication.
  • Use of medications known to affect free fatty acid (FFA) or adipose tissue metabolism, including, but not limited to, beta blockers, niacin and pioglitazone.
  • Pregnant women, prisoners or other special vulnerable category of participants.

More information

Publicaciones

Publications are currently not available
.
CLS-20151354

Mayo Clinic Footer